| Dataset | DGIdb Drug Targets 2026 |
| Category | physical interactions |
| Type | drug |
| Description | Amfenac in which the the hydrogen at the 4 position of the benzoyl group is substituted by bromine. It is used for the management of ocular pain and treatment of postoperative inflammation in patients who have undergone cataract extraction. It was withdrawn from the US market in 1998, following concerns over off-label abuse and hepatic failure. (Chemical Entities of Biological Interest Ontology, CHEBI_240107) |
| External Link | https://dgidb.org/results?searchType=drug&searchTerms=BROMFENAC |
| Similar Terms | |
| Downloads & Tools |
2 interacting proteins for the BROMFENAC drug from theDGIdb Drug Targets 2026 dataset.
